Previous studies have shown that PCa has low sensitivity to immune checkpoint blockade treatment owing to a lack of T cell infiltration and Type-I/II IFN characteristics (Annels et al., 2021). The gene discussed is IFNA1; the disease is posterior cortical atrophy.